Company ProfilePremium

Incannex Healthcare Limited

Company Profile Analysis

Ticker: IXHL

ESOMAR 23 Corporate BadgeISO Certifications Badge
Incannex Healthcare Limited - Company showcase

Year Founded & Workforce

2001

12 Employees

Incannex Healthcare Limited logo

Incannex Healthcare Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Incannex Healthcare Limited Overview

Incannex Healthcare is a micro-cap, clinical-stage biopharmaceutical company that is Australian in origin and now U.S.-domiciled. It develops oral fixed-dose combination drugs and psychedelic-assisted therapies for chronic conditions with poor existing treatments. Its strategy depends on IHL-42X, a once-nightly combination of dronabinol (synthetic THC) and acetazolamide for obstructive sleep apnea (OSA). IHL-42X showed statistically significant AHI reductions in the Phase 2 portion of RePOSA and holds FDA Fast Track designation. It is now in DReAMzz, a nine-arm dose-confirmation study expected to finish in mid-2027. The second asset is PSX-001, synthetic psilocybin with structured psychotherapy for generalized anxiety disorder (GAD). PSX-001 met its primary endpoint in the Australian PsiGAD1 Phase 2 trial, and the company is redesigning its next study. The company has no product revenue. As of 30 June 2026 it held USD 67.7 M of cash against a market capitalization near USD 40 M, which implies a negative enterprise value. It carries heavy dilution history, governance concerns, and an emerging oral-OSA competitor, Apnimed's AD109, which has a PDUFA date of 28 Feb 2027.


Company's own description (paraphrased from 10-K FY2026)

In its FY2026 Form 10-K, Incannex describes itself as a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious chronic conditions. The development priority is IHL-42X for OSA. The company is also deciding the next clinical plan for PSX-001 in GAD and whether to develop IHL-675A further in inflammatory conditions. It states that its three lead programs were created internally and prioritized for their potential to offer new therapeutic approaches. The stated strategy has four pillars:

  • advance lead candidates through pivotal and registrational programs toward FDA NDAs;

  • pursue expedited FDA pathways (Fast Track, Breakthrough, priority review, accelerated approval) and the 505(b)(2) route;

  • maintain a global IP estate;

  • retain flexibility to partner or license assets to maximize pipeline value.

After U.S. approval, it intends to expand to the EU, UK, Japan, Australia and Canada.

Business model

DimensionCharacterization
StageClinical-stage; no approved products; no product revenue
Revenue model (current)Effectively nil. FY2025 revenue was USD 86 K from clinic services (Clarion Clinics model psychedelic-therapy clinic). FY2026 revenue was USD 0 (10-K FY2026).
Revenue mix (product / service / subscription / licensing)0% / ~100% of trivial historical revenue from clinic services / 0% / 0%
Intended future modelBranded prescription pharmaceuticals (NDA route, largely 505(b)(2) for cannabinoid combinations), potentially commercialized directly in the U.S. or via partners/licensees; psychedelic-assisted therapy delivered through specialist clinics (JV with Mind Medicine Australia)
Value-chain positionAsset originator and developer. Outsources manufacturing (Procaps for IHL-42X/IHL-675A; Ardena US, formerly Catalent Pharma Solutions, for PSX-001 cGMP), clinical execution (CROs; 14 U.S. sites for DReAMzz) and packaging/labeling (U.S. secondary packaging vendor).
Non-dilutive fundingAustralian R&D Tax Incentive (48.5% refundable offset for eligible spend for companies with turnover < A$20 M): USD 1.76 M benefit recognized FY2025 and USD 4.66 M FY2026; A$11.2 M+ cash received in calendar 2026
Customer types (prospective)Sleep physicians, pulmonologists, primary care (OSA); psychiatrists and specialist clinics (GAD); rheumatologists (RA); payers/PBMs in the U.S.
End-marketsOSA (sleep-disordered breathing); anxiety disorders (GAD); inflammatory/autoimmune disease (RA, potentially IBD, COPD, asthma)

Independent characterization

Incannex is best understood as a single-asset optionality vehicle (IHL-42X) with one secondary, partially de-risked psychiatric asset (PSX-001). It has a deep but largely dormant "secondary asset" shelf (25 additional candidates, mostly inherited from the 2022 APIRx acquisition). The scientific thesis is to combine two approved, off-patent molecules with distinct mechanisms at lower doses, aiming for synergy and tolerability. The regulatory thesis is the 505(b)(2) pathway, which leverages existing safety data. FDA's combination rule requires that each component contribute to efficacy. That is why the originally designed RePOSA Phase 3 was factorial (IHL-42X vs. each component vs. placebo), and why dose-ratio optimization (DReAMzz) now precedes Phase 3.

The model is capital-light (12 employees, outsourced CMC/clinical), and Australian tax incentives subsidize it. Its persistent constraint is a small market capitalization relative to Phase 3 costs, which has historically forced highly dilutive financings: pre-split shares rose from 17.6 M (Aug 2024) to ~358 M (Feb 2026). The balance-sheet reset in FY2026 (USD 78.7 M of share-issuance proceeds) temporarily removed near-term financing pressure. It does not fund a full Phase 3 OSA program, which in the original RePOSA design targeted 560+ patients globally.

Strategy

Stated strategic themes (10-K FY2026, paraphrased)

  1. Advance lead candidates to registration. Pursue FDA NDAs for IHL-42X and PSX-001, then expand to the EU, UK, Japan, Australia and Canada.

  2. Seek streamlined regulatory pathways. Leverage Fast Track (granted for IHL-42X); seek further expedited designations; use 505(b)(2) for the cannabinoid combinations.

  3. Maintain a strong IP portfolio. File on compositions, methods, patient selection, formulations and processes in the U.S., Europe, Japan, Israel and other markets.

  4. Maximize pipeline value. Keep optionality for partnerships, licensing and collaborations.

Clinical approach (company framing). Combination therapy at lower doses of each agent improves tolerability and creates synergy. The psychotherapy wrapper around PSX-001 is designed to optimize outcomes and safety. Australian early-stage work captures R&D rebates before U.S. pivotal development.

Strategic initiatives — last 24 months

DateInitiativeTypeStatus
Sep 2024Arena Investors convertible debenture (up to USD 10 M) and USD 50 M equity lineFinancingDebentures extinguished FY2025; equity line registered (61.4 M pre-split resale shares)
Nov 2024Pause, then termination, of IHL-675A Phase 2Portfolio pruningComplete
Q3 FY2025Formation of OSA Clinical Advisory Board; later expandedClinical / regulatoryActive; input into DReAMzz design
May 2025Elimination of all Series A warrants (≈347.2 M pre-split shares of potential dilution)Capital structureComplete
Jun 202550:50 MMA Clinics JV (Melbourne)Commercial infrastructure (psychedelics)Operating; equity-accounted
Aug 2025USD 20 M share repurchase programCapital allocationUSD 9.1 M executed by May 2026; program expiry 30 Aug 2026
Dec 2025FDA Fast Track for IHL-42XRegulatoryGranted
Feb 20261:30 reverse split for Nasdaq complianceListingCompliance regained 16 Mar 2026
Mar 2026"Enhanced development pathway": DReAMzz dose-optimization study before a streamlined Phase 3R&D strategyEnrolling
2,026Termination of ATM with Curvature Securities and A.G.P./Alliance Global PartnersFinancingComplete
2,026Shelf registration for up to USD 150 M of securitiesFinancing capacityEffective status per filing (date n/d)
2,026PSX-001 Phase 2 redesign to differentiate vs psychedelic competitorsR&D strategyOngoing; next decision = final clinical plan

ESG / sustainability commitments. None announced.

Cost programs. Cost containment cut quarterly R&D and SG&A in FY2025 (Stonegate). No formal savings target disclosed.

Medium-term guidance

ItemGuidanceSource
Cash runwaySufficient for at least 12 months from the 10-K filing date (Sep 2026). Earlier (Jan 2026): runway "well into 2027".10-K FY2026; PR 14 Jan 2026
DReAMzz completionMid-202710-K FY2026
Phase 3 IHL-42XDesign to follow DReAMzz analysis; no start date guided10-K FY2026
PSX-001Finalize clinical development plan; no timeline guided10-K FY2026
OpexR&D and G&A expected to increase substantially10-K FY2026
RevenueNone expected near termShelf summary (Quartr)
Financial targetsNo revenue, margin or EPS targets issued—

Products & Services

Incannex has no marketed pharmaceutical products. The catalog below is organized by therapeutic franchise within the single R&D segment.

Lead franchise — Sleep-disordered breathing

AttributeDetail
MechanismDronabinol (synthetic Δ9-THC) acts on cannabinoid receptors, which the company believes dilates the airway. Acetazolamide (carbonic anhydrase inhibitor) induces mild metabolic acidosis that increases respiratory drive. Both individually reduce AHI.
DosingOnce daily, orally, ~1 hour before bed
Doses testedLow: 2.5 mg dronabinol + 125 mg acetazolamide. High: 5 mg + 250 mg (RePOSA). DReAMzz tests a 3×3 matrix: dronabinol 2.5/5/7.5 mg × acetazolamide 125/250/375 mg.
Target patientsOSA patients who are non-compliant with, intolerant of, or naïve to PAP. The company emphasizes the non-obese segment (it estimates >60% of patients are non-obese) not addressed by tirzepatide.
Clinical statusPhase 2 POC (Australia, n=11) complete. BA/BE study positive (Jan 2025). RePOSA Phase 2 (n=121, 16 U.S. sites) completed Jul 2025. DReAMzz Phase 2 dose-confirmation started May 2026, completion estimated mid-2027. Phase 3 planned thereafter.
Key RePOSA resultsStatistically significant % AHI reduction vs placebo for both doses (p<0.05). Maximum individual AHI reductions up to 83% (high) and 79% (low). >30% AHI reduction in 33.3% (low) and 41.2% (high). >50% AHI reduction in 13.9% (low) and 14.7% (high). Significant ODI improvement in both arms. PGI-C improvements (low dose). WASO −29.8% and supine AHI −30.3% (high dose). REM sleep not reduced. No SAEs. 57.6% of exit-interview participants perceived improvement, 89.5% of whom called it meaningful.
RegulatoryFDA IND; Fast Track designation (Dec 2025); intended 505(b)(2) NDA leveraging reference listed drugs
ManufacturingProcaps Group S.A. (oral fixed-dose formulation); DReAMzz supply manufactured and imported to U.S. secondary packager
IP2 granted patents (U.S., Japan; expire 2041) + 18 pending applications as of 1 Sep 2026 across AU, CA, CO, EP, IL, JP, NZ, US, UAE, HK
Launch yearNot applicable (pre-registration). Earliest NDA timing is not guided; it depends on a Phase 3 starting after mid-2027.
Pricing—

IHL-42X (dronabinol + acetazolamide), oral fixed-dose combination for OSA

Sources: 10-K FY2026; company PRs (Mar, May, Jul, Aug 2026): ### Psychiatry franchise

AttributeDetail
ProductOral synthetic psilocybin; two therapeutic dosing sessions plus preparation and integration psychotherapy (up to 11 non-drug sessions over ~10 weeks in PsiGAD1)
Target patientsAdults with moderate-to-severe GAD
Clinical statusPsiGAD1 Australian Phase 2 (randomized, triple-blind, active-placebo-controlled; 73 participants) complete; full results Aug 2025. FDA-cleared IND authorizing a Phase 2b. The company is redesigning the Phase 2 study to differentiate from competitors.
Key resultsPrimary endpoint met. Mean 12.8-point HAM-A reduction sustained over 11-week follow-up. 44.1% achieved >50% HAM-A reduction. 27% remission (≈5× placebo). GAD-7 −7.4 vs −3.5 (p<0.0004). Sheehan Disability −6.0 vs −1.3 (p<0.007). PHQ-9 −3.9 vs −0.3 (p<0.005). Personal Wellbeing Index +10.6 vs +2.7 (p<0.002). No SAEs; one dropout among 73.
ManufacturingArdena US LLC (formerly Catalent Pharma Solutions LLC) for cGMP drug product
IPPatent strategy "being explored" (no granted composition patents disclosed)
Delivery channelClarion Clinics model clinic; 50:50 JV with Mind Medicine Australia (Melbourne) supplying an integrated services platform to Australian Authorised Prescribers
PricingNot disclosed for PSX-001. Third-party report cites Clarion's nine-month treatment package price (non-PSX-001, TGA Authorised Prescriber context).
AttributeDetail
OfferingPsilocybin- and MDMA-assisted therapy under Australia's Authorised Prescriber scheme (treatment-resistant depression, PTSD), plus clinician training and governance services
RevenueUSD 12 K (FY2024), USD 86 K (FY2025), USD 0 (FY2026; activity moved into equity-accounted JV)
Strategic roleReal-world commercialization template for psychedelic-assisted care if PSX-001 is approved

PSX-001 (synthetic psilocybin) + structured psychotherapy for GAD

Sources: 10-K FY2026; PR 17 Jun 2025; Mugglehead: Clinic services (Clarion Clinics / MMA Clinics JV)

Inflammation franchise

AttributeDetail
TargetRheumatoid arthritis (initial); potential IBD, COPD, asthma, ARDS, bronchitis
StatusPhase 1 (n=36; vs Epidiolex and Plaquenil) complete and published in Scientific Reports (2025): well tolerated and both APIs bioavailable. Australian Phase 2 RA trial (planned 128 subjects, 4 arms, RAPID3 at 24 weeks) paused Nov 2024 and terminated for slow enrollment; no conclusions possible. Future development under review.
PK highlightsCBD Cmax 1.57× vs Epidiolex, Tmax 26% faster. HCQ Tmax 46% slower than Plaquenil with similar exposure (trends, p>0.05).
ManufacturingProcaps
Status noteDeprioritized; development contingent on resources (10-K FY2026; Quartr FY2026 summary)

IHL-675A (cannabidiol + hydroxychloroquine sulfate), oral fixed-dose combination

Secondary / dormant assets

Asset groupDescriptionEstimated market (company-cited)Status
25 secondary assetsProof-of-concept in preclinical, Phase 1 or Phase 2 (company claim)—Not resourced
Topical cannabinoid candidatesSkin conditionsUSD 1.8 B global (2021)Preclinical/early
Chewable cannabinoid (APIRx gum delivery)Smoking cessationUSD 28.9 B global (2024), 9.2% CAGREarly
Opioid-addiction candidateOpioid use disorderUSD 4.59 B global (2021)Early
IHL-216ATraumatic brain injury / concussion (historical program with Monash University)—Preclinical; no recent disclosure
IHL-675A in IBD / pulmonaryInflammatory bowel disease; COPD and asthmaUSD 21 B U.S. IBD (2021); USD 36.7 B U.S. COPD + asthma (2022)Concept

Source: 10-K FY2026; 6-K annual report FY2022.

Financial Narrative

Income statement

Sources: 10-K FY2024 (FY2023, FY2024); 10-K FY2025; 10-K FY2026. FY2023 G&A derived as total opex less R&D and IPR&D (consistent with the company's FY2024 results PR, which cited ~USD 8.0 M). Gross profit is not reported (no cost of revenue). EBITDA is not disclosed. D&A is immaterial (capex of tens of thousands of USD per quarter), so EBITDA approximates the operating loss.

Other income / expense detail (USD M)

Source: 10-K FY2026 MD&A. The FY2025 residual of ~USD -22.7 M (derived: total other −23.096 less itemized lines above and USD 0.129 M warrant issuance costs) reflects financing-related fair-value losses on warrants, convertible instruments and the Series A warrant cancellation. Management attributes the FY2026 improvement mainly to lower financing-related losses and higher R&D tax incentives (Quartr FY2026 summary). FY2024 other income of USD +11.6 M included R&D tax incentive and other items not itemized in sources reviewed.

Per-share data

Sources: 10-K FY2024; 10-K FY2025 (as reported). FY2026 EPS per Yahoo Finance TTM (USD −1.66; 9-month FY2026 10-Q EPS was −1.51). Split-adjusted FY2023–FY2025 and pre-split FY2026 values are derived (×30 / ÷30). The FY2026 10-K retrospectively restates per-share data for the split. The collapse in loss per share reflects the >20× increase in weighted shares, not improved economics.

Margins

All revenue-based margins (gross, operating, EBITDA, net) are n/m: revenue was nil or below USD 0.1 M in every year. Revenue CAGR is n/m.

Balance sheet

Period-end balance-sheet aggregates (USD M)

Sources: FY2024 current assets and liabilities from the company's Q2 FY2025 results tables (16,202 / 5,830 USD K). Other values from aggregator XBRL histories (vcpscanner/Seeking Alpha), consistent with digrin (FY2025 total assets 20.4, liabilities 7.1). FY2026 full balance sheet not captured in sources reviewed. Interim reference points: total assets USD 75.0 M and liabilities USD 1.6 M (31 Dec 2025); USD 80.3 M and USD 5.0 M (31 Mar 2026).

Cash and accumulated deficit (USD M)

Sources: Q1 FY2025 PR (30 Jun 2024 cash USD 5.9 M); 10-K FY2026 (FY2025, FY2026). Accumulated deficit: USD 174.4 M (31 Mar 2026), USD 176.9 M (30 Jun 2026).

Cash flow: notes and sources

Source: edgar.tools XBRL extract of 10-K FY2025 (rounded to USD M). Net cash from financing: ~USD 8 M (FY2023) and ~USD 21 M (FY2025). FY2026 cash-flow statement totals were not captured. Partial FY2026 data: six-month operating burn USD 13.8 M to 31 Dec 2025 (10-Q Q2 FY2026); FY2026 share-issuance proceeds USD 78.7 M (10-K FY2026 / Quartr). Capex is de minimis (USD 2–62 K per quarter). Free cash flow ≈ operating cash flow. Dividends paid: nil every year.

Ratios

All derived from the tables above. FY2026 ROE ≈ −26% on Dec-2025 equity of USD 73.4 M (derived; full FY2026 equity n/d). ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are n/m for a pre-revenue company with net cash and no debt. Debt/equity ≈ 0 at FY2026.

Commentary on trends, inflections and drivers

FY2023 — the APIRx year. The FY2023 loss of USD 48.8 M is dominated by a non-cash USD 35.3 M charge for in-process R&D acquired with APIRx. US GAAP requires immediate expensing of IPR&D acquired in an asset acquisition without alternative future use. Cash R&D was only USD 6.3 M. This sets a pattern: headline losses at Incannex are often driven by accounting events rather than operating intensity.

FY2024 — redomiciliation and public-company cost inflation. R&D roughly doubled to USD 12.9 M as RePOSA started in the U.S. and IHL-675A Phase 2 started in Australia. G&A more than doubled to USD 17.2 M. The company attributed this to the redomiciliation, Nasdaq listing of common stock, and expanded U.S. operations, and large equity awards also contributed: the CEO's FY2024 stock awards had a USD 5.5 M grant-date value (DEF 14A). Other income of USD 11.6 M (largely R&D tax incentive and non-operating items) cushioned the net loss to USD 18.5 M.

FY2025 — financing distress. Operating expenses fell 21% to USD 23.9 M through cost containment, and the company completed RePOSA Phase 2. The quarter to 31 Dec 2024 closed with only USD 2.1 M of cash. Survival financing came through Arena convertible debentures and an equity line (Sep 2024), a USD 12.5 M at-the-market-priced private placement, and Series A warrants. That structure produced ~USD 23 M of other expense, mostly fair-value losses and extinguishment costs, which took the net loss to USD 46.9 M. Pre-split share count rose ~11× in the year (17.6 M → 194.4 M).

FY2026 — recapitalization and pipeline pivot. The positive July–August 2025 readouts and December 2025 Fast Track enabled USD 78.7 M of equity raises, mainly through the ATM and the March 2026 registered direct. Cash rose to USD 67.7 M. R&D fell 52% to USD 5.2 M during the gap between RePOSA and DReAMzz. G&A rose 36% to USD 17.8 M, driven by a USD 5.0 M increase in stock-based compensation (from USD 2.6 M to USD 7.6 M) tied to May 2025 equity awards. G&A was therefore 3.4× R&D in FY2026, an unusual and unfavorable mix for a development-stage biotech. Management guides to substantially higher R&D and G&A ahead.

Inflection to watch. DReAMzz (9 doses, ~120 subjects, 14 sites, crossover) will lift R&D sharply in FY2027. A Phase 3 program, which RePOSA had originally sized at 560+ patients globally, will likely exceed current cash. The 10-K guides to cash sufficient for "at least 12 months" from the filing date. That is a weaker statement than the January 2026 claim of runway "well into 2027", and it implies further capital needs before Phase 3 completion.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

MetricFY2023FY2024FY2025FY2026

Total segment revenue (USD Mn)

00.0120.0860

Segment loss from operations (USD Mn)

-49.668-30.041-23.789-23.027

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Revenue YoY growth (%)

n/m

617-100

Share of total revenue (%)

100100

n/m

Group Entities

EntityJurisdictionFunction

Incannex Healthcare Inc.

Delaware, USA

Listed parent; Nasdaq registrant

Incannex Healthcare Limited

Victoria, Australia

Legacy operating company; R&D tax incentive claimant

Psychennex Pty Ltd

Victoria, Australia

Psychedelic medicine program entity (PSX-001)

Psychennex Licensing and Franchising Pty Ltd

Victoria, Australia

Clinic licensing/franchise model

Clarion Clinics Group Pty Ltd

Victoria, Australia

Psychedelic-assisted therapy clinic group

Clarion Model Clinic Pty Ltd

Victoria, Australia

Model clinic operations (source of FY2024–FY2025 service revenue)

APIRx Pharmaceutical USA, LLC

Delaware, USA

Acquired 2022; cannabinoid IP holder

APIRx Pharmaceuticals Holding BV

IJsselstein, Netherlands

APIRx IP/holding entity

Mind Medicine Australia Clinics (JV, 50%)

Australia

Equity-accounted JV; share of loss USD 37 K in FY2026

Income Statement

MetricFY2023FY2024FY2025FY2026

Revenue (USD Mn)

00.0120.0860

Research and development expense (USD Mn)

6.30912.87910.7475.210

Acquired in-process R&D (USD Mn)

35.347000

General and administrative expense (USD Mn)

8.01217.17413.12817.817

Total operating expenses (USD Mn)

49.66830.05323.87523.027

Operating income / loss (USD Mn)

-49.668-30.041-23.789-23.027

Total other income / expense, net (USD Mn)

0.85711.612-23.0963.725

Pre-tax income / loss (USD Mn)

-48.811-18.429-46.885-19.302

Income tax expense (USD Mn)

00.03000

Net income / loss (USD Mn)

-48.811-18.459-46.885-19.302

Key Financials

MetricFY2025FY2026

R&D tax incentive (USD Mn)

1.7564.658

Foreign exchange gain / loss (USD Mn)

-0.289-0.013

Interest income (USD Mn)

0.0620.021

Interest expense (USD Mn)

-0.3030

Loss on extinguishment (USD Mn)

-1.4720

Share of JV loss (USD Mn)

0-0.037

Per-Share Data

MetricFY2023FY2024FY2025FY2026

EPS basic/diluted as originally reported, pre-split (USD)

-3.32-1.15-1.35-0.055

EPS basic/diluted split-adjusted 1:30 (USD)

-99.60-34.50-40.50-1.66

Dividends per share (USD)

0000

Balance Sheet

MetricFY2023FY2024FY2025

Total assets (USD Mn)

35.8017.0520.45

Total current assets (USD Mn)

34.6116.2019.96

Total liabilities (USD Mn)

4.455.837.06

Total stockholders' equity (USD Mn)

31.3411.2213.39

Key Financials (FY2024–FY2026)

MetricFY2024FY2025FY2026

Cash and cash equivalents (USD Mn)

5.915.067.7

Balance-sheet Item Details

Balance-sheet itemLatest status

Total debt (short/long)

No financial debt at 30 Jun 2026. Interest expense nil in FY2026. Arena convertible debentures (USD 4.6 M initial draw Oct 2024) were extinguished in FY2025 (loss on extinguishment USD 1.47 M). Lease liabilities ~USD 0.11 M (Mar 2026).

Net debt

Net cash ≈ USD 67.7 M (30 Jun 2026)

Goodwill & intangibles

Nil under US GAAP; APIRx IP was expensed as IPR&D in FY2023

Working capital

Strongly positive. Example: Dec 2025 current assets USD 74.7 M vs current liabilities ≈ USD 1.5 M.

R&D tax incentive receivable

~USD 4 M at 30 Jun 2025 (XBRL extract); A$5.1 M refund received Aug 2026

Cash Flow

MetricFY2023FY2024FY2025

Net cash used in operating activities (USD Mn)

-11-16-13

Capital return

Capital returnDetail

Buybacks

USD 20 M program authorized 22 Aug 2025 (expiry 30 Aug 2026). USD 1.5 M repurchased by 31 Dec 2025; cumulative USD 9.1 M (~2.1 M post-split shares) by 15 May 2026. Reactivated 27 Mar 2026.

Dividends

None paid; none expected

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025

ROE on period-end equity (%)

-155.7-164.5-350.1

ROA on period-end assets (%)

-136.3-108.3-229.3

Current ratio (x)

9.022.882.86

Revenue by Region

RegionFY2023FY2024FY2025FY2026

Australia revenue (USD Mn)

00.0120.0860

Americas revenue (USD Mn)

0000

EMEA revenue (USD Mn)

0000

Share Price & Returns

ReferencePriceSource

30 Jun 2025 close (pre-split)

0.2157 (≈6.47 split-adjusted, derived)

DEF 14A

31 Dec 2025 close

10.74

10-K FY2026 cover

27 Feb 2026

First post-split trading day

8-K

27 Mar 2026

~3.26

Robinhood

15 May 2026 close

3.79

Benzinga

2 Oct 2026 close

3.21

Yahoo Finance

52-week range

2.49 – 14.94

Yahoo Finance

Performance (derived)

Return

—

YTD 2026 (31 Dec 2025 → 2 Oct 2026)

≈ -70%

—

Since FY2025 year-end (30 Jun 2025 split-adjusted → 2 Oct 2026)

≈ -50%

—

1-year, 3-year, 5-year total return

Directionally deeply negative across all horizons given the 1:30 reverse split and the 2024–2025 dilution.

—

Valuation Snapshot

MetricValueBasis

Market capitalization

~USD 40.3 M

12.54 M shares × USD 3.21

Enterprise value

≈ USD -27 M (derived; cash at 30 Jun 2026 less market cap; actual cash lower after Q1 FY2027 burn)

Derived

P/E

n/m (loss-making; TTM EPS USD -1.66)

Yahoo

EV/EBITDA, EV/Sales

n/m

—

P/B

≈ 0.55× vs Dec-2025 equity of USD 73.4 M (derived; FY2026 book n/d)

Derived

Peer comparison

Most clinical-stage OSA/psychedelic peers trade at positive EVs. A negative EV signals market skepticism about IHL-42X's commercial prospects and/or expected cash burn and dilution.

Qualitative

Capital Markets

ItemDetail

Dividend policy

None paid; none anticipated

Buyback

USD 20 M authorization (22 Aug 2025 – 30 Aug 2026). USD 9.1 M used (~2.1 M shares) through 15 May 2026. Renewal status after expiry not disclosed in sources reviewed.

Shares outstanding

12,544,627 (24 Sep 2026)

Warrants

2.0 M March 2026 common warrants (USD 6.50 strike, 5-year); legacy warrants in smaller amounts

Equity plan

2023 Plan with 5% annual evergreen (FY2027–FY2033)

Shelf

Up to USD 150 M

Credit ratings

None (Moody's / S&P / Fitch: not rated)

Debt maturity profile

No financial debt; minor lease liabilities (~USD 0.1 M)

Analyst Conclusions

Management guidance

  • DReAMzz completion: mid-2027. Results to inform Phase 3 design.

  • Cash sufficient for at least 12 months from the FY2026 10-K filing date.

  • R&D and G&A to rise substantially (DReAMzz, PSX-001 planning, commercialization preparation).

  • PSX-001 next-step plan to be finalized. IHL-675A contingent on resources.

  • No revenue guidance.

Consensus growth expectations

No credible consensus revenue or EPS forecasts exist. MarketScreener lists forward P/E estimates of −2.7× (FY2027) and −1.78× (FY2028), implying continued losses. Analyst count is unknown.

Bull case

  1. Deep value floor. Cash of USD 67.7 M against a ~USD 40 M market capitalization means investors pay nothing for two positive Phase 2 assets, Fast Track, and 25 shelf assets. Buybacks below cash per share compound the asymmetry.

  2. Category validation by AD109. If the FDA approves Apnimed's AD109 by 28 Feb 2027, the oral OSA category is validated. Payers and physicians then become receptive to second-generation, differentiated agents, particularly ones with a distinct mechanism (cannabinoid and respiratory drive) that may suit AD109 non-responders or combine with GLP-1s. That could make IHL-42X a partnering target.

  3. Dose optimization upside. RePOSA tested only 2 of the 9 ratios now in DReAMzz. If higher dronabinol (7.5 mg) or acetazolamide (375 mg) arms deliver deeper responder rates without impairment, the Phase 3 effect size improves materially. Fast Track enables rolling review.

Bear case

  1. Clinically modest efficacy. Only ~14–15% of patients achieved >50% AHI reduction in RePOSA, and the stock fell ~18% on topline. Against AD109's two Phase 3s and GLP-1 weight-loss effects, IHL-42X may struggle for differentiation, and higher THC doses heighten next-day impairment and scheduling issues.

  2. Funding gap and dilution. Guided runway is only 12 months, while a factorial Phase 3 for a fixed-dose combination could cost multiples of current cash. G&A already exceeds R&D 3.4×, and history (pre-split shares up ~20× in 18 months) suggests future raises will be dilutive.

  3. Governance and capital allocation. Large equity grants to the CEO and non-independent Chair, a USD 790 K CEO salary, an AGM held in Dubai, procedural proxy errors, and the decision to spend USD 9.1 M on buybacks while Phase 3 remains unfunded point to misaligned priorities.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
By ~28 Oct 20262026 DEF 14A: compensation, Class III director elections (Latham, Valentine), any new equity plan requests
Nov 2026Q1 FY2027 10-Q: cash burn post-DReAMzz start; buyback renewal/termination
H2 2026 – H1 2027DReAMzz enrollment pace across 14 U.S. sites (target ~120 subjects)
H2 2026PSX-001 development-plan decision (Phase 2b redesign; partnering?)
28 Feb 2027FDA action on Apnimed AD109 (competitive read-through)
2,027Definium DT120 NDA filing in GAD (competitive read-through for PSX-001)
OngoingU.S. cannabis and psilocybin rescheduling actions
Mid-2027DReAMzz completion and dose selection (just beyond the 12-month window)
OngoingEquity issuance under the USD 150 M shelf; warrant exercises; evergreen equity-plan expansion

Analyst verdict

Incannex has climbed out of the 2024–2025 financing hole. It enters FY2027 with USD 67.7 M of cash, no debt, two programs with positive randomized Phase 2 data, and FDA Fast Track for its lead OSA candidate. The market's verdict is nonetheless blunt: a market capitalization near USD 40 M implies a negative enterprise value. In effect, investors are discounting future burn, dilution and governance risk more heavily than the scientific optionality.

On the evidence, that skepticism is partly earned. RePOSA met its primary endpoint, but the distribution of benefit was narrow: roughly one in seven patients halved their AHI. The company's own decision to insert a nine-arm DReAMzz study before Phase 3 concedes that the optimal dose ratio is unknown, and it pushes pivotal data toward 2029 or later. Meanwhile, Apnimed's AD109 is under FDA review with a February 2027 action date. If approved, it becomes the first oral OSA drug and the benchmark IHL-42X must beat. In GAD, Definium's DT120 has produced two positive Phase 3 trials with a single-dose regimen, a high bar for PSX-001's multi-session psychotherapy model.

Capital allocation and governance are the swing factors. G&A was 3.4× R&D in FY2026, driven by equity awards to insiders. Buybacks consumed USD 9.1 M that Phase 3 will likely need. Board independence is only modestly above the minimum.

Overall assessment: speculative, catalyst-driven, high risk. The investment case rests on three things: (1) DReAMzz identifying a clearly superior ratio; (2) AD109's approval validating rather than foreclosing the category; and (3) management converting the cash cushion into a partnered Phase 3 rather than serial dilution. Until DReAMzz data arrive in mid-2027, the stock is likely to trade as a cash shell with an option attached. Investors should value it at a discount to net cash adjusted for projected burn, plus a modest probability-weighted value for IHL-42X. Material upside requires partnering evidence or unexpectedly strong dose-optimization data.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureAgePrior rolesEducation

Joel Latham

President, CEO and Director

Group since 2016; CEO of Australian company since Jun 2018; CEO of Inc. since Jul 2023

36

Senior roles at Mars Foods, Tabcorp, Philip Morris International

Not disclosed in proxy

Joseph Swan

CFO, Treasurer and Secretary

CFO since Feb 2024; Treasurer/Controller Jul 2023 – Feb 2024; Head of Finance from Nov 2021

34

HLB Mann Judd (audit supervisor), INPEX Australia (internal audit), Deloitte Australia (analyst)

B.Com (Accounting), University of Western Australia; Chartered Accountant

Lekhram Changoer

Chief Technology Officer (services agreement)

CTO since Jul 2023 (Australian company since Jun 2022)

59

Co-founder/CTO APIRx (2019–2023); co-founder/CTO AXIM Biotechnologies (2014–2020)

MSc/BSc, University of Groningen and Rijkshogeschool Groningen

Luigi M. Barbato, M.D.

Chief Medical Officer

Since 21 Oct 2024

62

Global Medical Lead, Jazz Pharmaceuticals; Global Senior Medical Director, AbbVie; Biogen Idec, Novartis, Stiefel (GSK), Solvay; former Clinical Assistant Professor of Psychiatry, Emory

M.D., St George's University; B.S. Biology, St Peter's University

Board of Directors

NameRoleIndependentClass / termAgeBackground

Troy Valentine

Non-executive Chair (since Nov 2023; Australian board chair since Dec 2017)

No

Class III (to 2026 AGM)

52

30+ years in broking/corporate finance (Hartley Poynton, Patersons/Canaccord); co-founder of Alignment Capital Pty Ltd; B.Com, UWA

Joel Latham

CEO and Director

No

Class III (to 2026 AGM)

36

See above

Peter Widdows

Director; Audit and Compensation Committee Chair; audit committee financial expert

Yes

Class I (to 2027 AGM)

59

Former Heinz regional CEO Asia/Australasia and Heinz Australia CEO; Chair of Youi Insurance and Sunny Queens; FCA (ICAEW)

Dr George Anastassov

Director; Audit Committee member

Yes (per board determination)

Class II (nominated to 2028)

61

APIRx co-founder/MD; AXIM Biotechnologies co-founder/CEO; craniomaxillofacial surgeon; MD (Sofia), DDS (NYU), MBA (Tennessee); Mt Sinai faculty

Robert Clark

Director; Audit and Compensation Committee member

Yes

Class II (nominated to 2028)

65

VP U.S. Regulatory Affairs at Novo Nordisk (since 2012); VP Worldwide Regulatory Strategy at Pfizer (1992–2012); MS Pharmacology, New York Medical College

Directors' Remuneration

NameYearSalaryBonusStock awardsAll otherTotal

Joel Latham (CEO)

FY2025

656,464297,6890173,5861,127,739

Joel Latham (CEO)

FY2024

595,95805,494,000126,1246,216,082

Joseph Swan (CFO)

FY2025

150,65030,130020,413201,193

Joseph Swan (CFO)

FY2024

107,94026,873117,33211,862264,007

Luigi Barbato (CMO)

FY2025

264,0630233,1040497,167

Non-employee director (FY2025)

Fees

Other (superannuation)

Total

———

Troy Valentine

312,76117,701330,462———

Dr George Anastassov

132,0000132,000———

Peter Widdows

94,89812,298107,196———

Robert Clark

75,000075,000———

Board & Management Changes

DateChange

Nov 2023

Australian board reconstituted as Incannex Healthcare Inc. board at redomiciliation

Feb 2024

Joseph Swan appointed CFO

Oct 2024

Dr Luigi Barbato appointed CMO

Oct 2024

Peter Widdows nominated as sole Class I director (2024 AGM); former director Sud Agarwal referenced in 2024 proxy

Dec 2025

Anastassov and Clark re-nominated as Class II directors (2025 AGM, held hybrid with an in-person venue in Dubai)

2026

No C-suite changes identified in sources reviewed

Major Shareholders

Holder (as of 10 Oct 2025, pre-split)Shares% of 347.7 M

Joel Latham

1,686,822

<1

Troy Valentine (direct + associated entities)

1,084,284

<1

Dr George Anastassov

769,721

<1

Lekhram Changoer (via Prash BV)

639,549

<1

Peter Widdows

281,897

<1

Robert Clark

100,000

<1

All directors and officers (8 persons)

4,633,6271.33

Competitive Landscape

Competitors by Segment

IndicationCompetitorAsset / approachStage (Oct 2026)Relative positioning vs Incannex

OSA

Apnimed (private)

AD109 (aroxybutynin 2.3 mg + atomoxetine 75 mg), once-nightly oral

NDA accepted Jul 2026; PDUFA 28 Feb 2027; two positive Phase 3s (SynAIRgy, LunAIRo); up to USD 150 M HCRx credit facility

Likely first oral OSA pharmacotherapy; ~3–4+ years ahead of IHL-42X

OSA

Eli Lilly

Tirzepatide (Zepbound), approved for OSA in adults with obesity

Marketed

Treats obesity-driven OSA. Incannex positions IHL-42X for non-obese patients (company estimates >60% of patients).

OSA

Mineralys Therapeutics

Lorundrostat (aldosterone synthase inhibitor) explored in OSA

Clinical

Named by Incannex as an OSA drug-development competitor

OSA

Device incumbents (ResMed, Philips)

CPAP/PAP

Marketed standard of care

~50% discontinue CPAP within a year (10-K); the drug opportunity targets this gap

OSA

Inspire Medical Systems

Hypoglossal nerve stimulation (implant)

Marketed

Invasive; addresses PAP-intolerant moderate-severe patients

GAD

Definium Therapeutics (formerly MindMed; Nasdaq: DFTX)

DT120 (LSD) ODT, single dose, Breakthrough Therapy

Two positive Phase 3s in GAD (Voyage, Panorama) plus positive Phase 3 in MDD

Far ahead; sets a high efficacy bar (5.4-point placebo-adjusted HAM-A at week 12 in Voyage)

GAD / psychedelics

Helus Pharma (formerly Cybin)

Psychedelic programs

Clinical

Named in 10-K as GAD competitor

Psychedelics

Compass Pathways (Nasdaq: CMPS)

COMP360 psilocybin (TRD)

Late-stage

Psilocybin formulation/IP and scale competitor

Psychedelics

AtaiBeckley (acquired by Eli Lilly per 10-K)

Serotonergic/psychedelic programs

Clinical

Big-pharma-backed competitor

Psychedelics

GH Research (Nasdaq: GHRS)

GH001 inhaled mebufotenin

Clinical

Short-acting psychedelic competitor

GAD

Otsuka; Sunovion

Novel anxiolytic programs

Various

Named in 10-K

RA

Pfizer, AbbVie, Amgen, Novartis, Boehringer Ingelheim, Eli Lilly, Roche, BMS, AstraZeneca, Merck

Biologics, JAK inhibitors, csDMARDs

Marketed

Overwhelming incumbency; IHL-675A deprioritized

Cannabinoids

State-legal medical/recreational cannabis; CBD supplements

Unapproved products

Marketed (state level)

Possible substitution or price pressure if U.S. rescheduling to Schedule III proceeds

Peer Comparison FY2026

CompanyRevenueGrowthMarginsR&D intensityNotes

Incannex (FY2026)

USD 0

n/m

n/m

R&D USD 5.2 M (23% of opex)

Net loss USD 19.3 M; cash USD 67.7 M

Definium Therapeutics (Q1 2026)

~0 (pre-commercial)

n/m

n/m

—

Q1 2026 net loss USD 77.1 M; cash runway into 2028 (company)

Eli Lilly

n/d in this research cycle

———

Mega-cap; tirzepatide OSA label

Company Snapshot

12

Employees

$40.3M

Market Cap

2001

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Positive randomized Phase 2 in OSA. RePOSA (n=121, 16 U.S. sites) met its primary endpoint for both doses (p<0.05), improved ODI, and produced no SAEs (10-K FY2026).
  • FDA Fast Track for IHL-42X (3 Dec 2025) enables rolling NDA submission and potential priority review.
  • Second positive Phase 2 asset. PsiGAD1: 12.8-point HAM-A reduction; 27% remission (~5× placebo); one dropout of 73 (10-K FY2026).
  • Net cash exceeds market capitalization. Cash of USD 67.7 M (30 Jun 2026) vs ~USD 40 M market cap (Oct 2026); no financial debt.
  • Non-dilutive funding stream. R&D tax incentive of USD 4.66 M recognized in FY2026; >A$11.2 M received in calendar 2026.
  • IP runway. Two granted IHL-42X patents (U.S., Japan) to 2041 plus 18 pending to 2043. U.S. grant announced Jun 2026.

Weaknesses

  • Modest responder depth. Only 13.9% (low dose) and 14.7% (high dose) achieved >50% AHI reduction in RePOSA. The stock fell ~17.8% on topline day.
  • Cost structure skewed to overhead. FY2026 G&A of USD 17.8 M was 3.4× R&D of USD 5.2 M, inflated by USD 7.6 M of stock-based compensation.
  • Severe historical dilution. Pre-split shares grew from 17.6 M (Aug 2024) to ~358 M (Feb 2026), followed by a 1:30 reverse split. Accumulated deficit is USD 176.9 M.
  • Pipeline attrition. IHL-675A Phase 2 terminated for enrollment failure with no usable data.
  • Governance. Non-independent chair; 60% independent board; no nominating committee; compensation committee did not meet in FY2025; AGM procedural error; CEO FY2024 total pay of USD 6.2 M.
  • Thin organization. ~12 employees running a 14-site, 9-arm crossover study and CMC for two programs.

Opportunities

  • Non-obese OSA. The company estimates >60% of OSA patients are non-obese and therefore outside tirzepatide's label.
  • DReAMzz dose optimization could identify a ratio with materially better efficacy (7.5 mg dronabinol and 375 mg acetazolamide arms are newly tested).
  • Partnering / licensing. The 10-K explicitly retains optionality, and AD109's NDA validates the oral-OSA category for larger acquirers.
  • Psychedelic liberalization. DEA petition to reschedule psilocybin to Schedule II forwarded to HHS (Aug 2025); Australian clinic infrastructure via the MMA JV.
  • Secondary-asset monetization. 25 secondary candidates (smoking cessation, opioid addiction, dermatology) could be out-licensed.
  • Capital-return arbitrage. Buybacks below cash per share (USD 9.1 M executed) are accretive if burn is controlled.

Threats

  • AD109 first to market. PDUFA 28 Feb 2027 with two positive Phase 3s; could set efficacy, safety and pricing benchmarks before IHL-42X Phase 3 begins.
  • Definium's DT120. Two positive Phase 3s in GAD with Breakthrough designation make PSX-001's multi-session psychotherapy model less competitive.
  • THC scheduling and safety perception. All three candidates contain Schedule I substances requiring DEA approvals (10-K); next-day impairment and abuse-liability scrutiny.
  • Financing risk. Runway guided only to 12 months; the March 2026 warrants (USD 6.50 strike) and equity plan evergreen (5% per year) add dilution.
  • Listing fragility. Shares trade near USD 3 after the reverse split; the 52-week low is USD 2.49. A renewed bid-price deficiency would be unlikely near term but not impossible.
  • Regulatory combination rule. FDA may require factorial evidence that each component contributes, which enlarges Phase 3 size and cost (original RePOSA Phase 3 design was a four-arm, 52-week factorial).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
23 Apr 2025Nasdaq minimum-bid-price deficiency notice (8-K)Listing risk begins
15 May 2025Q3 FY2025 results: net loss USD 3.97 M; cash USD 6.71 M; RePOSA Phase 2 fully dosed (>120 patients); OSA Clinical Advisory Board formedPre-readout liquidity tight
15–16 May 2025Letter agreements permitting reduction of up to 50.4% of Series A warrantsDilution management
20 May 2025First Series A warrant cancellation trancheOverhang reduction
27 May 2025Special meeting approves reverse-split authority and equity plan amendmentEnabling actions
28 May 2025Binding agreement to cancel remaining 172 M Series A warrants (payment up to USD 12.2 M); 347.2 M total pre-split shares eliminatedCapital-structure cleanup
May 2025USD 12.5 M private placement priced at-the-marketFunds RePOSA completion
17 Jun 202550:50 JV with Mind Medicine AustraliaPsychedelic-therapy commercialization template
18 Jun 2025RePOSA Phase 2 database lockReadout timing confirmed
30 Jul 2025RePOSA topline: significant AHI reduction for both doses; stock fell ~17.8% on the dayEfficacy positive but market questioned effect size
8 Aug 2025Detailed RePOSA PROs and secondary endpointsSupports clinical meaningfulness
22 Aug 2025USD 20 M share repurchase authorizedCapital return despite cash need
26 Aug 2025Full PsiGAD1 Phase 2 results for PSX-001 (primary endpoint met)Second positive Phase 2
10 Sep 2025CEO salary raised to USD 790 K; USD 395 K discretionary bonusGovernance / compensation scrutiny
29 Sep 2025FY2025 10-K filed (net loss USD 46.9 M)Annual disclosure
30 Sep 2025Equity plan reserve raised to 77.2 M pre-split sharesLarge equity grants
21–22 Oct 2025Nasdaq grants 180-day extension; company signals reverse split if neededListing preservation
27 Oct 2025DEF 14A filed; AGM set for 18 Dec 2025 (hybrid, Dubai venue)Governance
3 Dec 2025FDA Fast Track designation for IHL-42X; stock up ~12.7% (21% pre-market)Major regulatory milestone
Dec 2025 – early 2026AGM adjourned and rescheduled over misclassification of the auditor-ratification proposal; Grant Thornton later ratified (110.3 M for, 7.9 M against)Procedural governance lapse
14 Jan 20262025 review: >USD 70 M cash, runway "well into 2027"Balance-sheet reset
25–27 Feb 20261:30 reverse split (≈358.3 M → ≈11.9 M shares); new CUSIP 45333F208Nasdaq compliance
12 Mar 2026Registered direct: 1,997,285 shares + 2,715 pre-funded warrants + 2.0 M common warrants (USD 6.50 strike, 5-year) at USD 5.00~USD 10 M gross; adds warrant overhang
12 Mar 2026Enhanced IHL-42X pathway: DReAMzz dose optimization before streamlined Phase 3Phase 3 delayed but de-risked
16–17 Mar 2026Nasdaq confirms regained bid-price complianceListing risk removed
27 Mar 2026Share buyback reactivatedSignals perceived undervaluation
2026 (date n/d)ATM agreements with Curvature Securities and A.G.P. terminatedReduces dribble dilution
15 May 2026Q3 FY2026: nine-month net loss USD 16.8 M; cash USD 74.5 M; USD 9.1 M repurchases (~2.1 M shares)Liquidity peak
May 2026DReAMzz officially commences; all 14 sites identified; clinical supply manufacturedExecution
25 Jun 2026U.S. patent granted for IHL-42X in OSAIP strengthening
14 Jul 2026(Competitor) FDA accepts Apnimed's AD109 NDA for OSA; PDUFA 28 Feb 2027Competitive threat: first oral OSA drug likely years ahead of IHL-42X
23 Jul 2026DReAMzz participant screening beginsExecution
11 Aug 2026A$5.1 M R&D tax incentive refund; >A$11.2 M non-dilutive capital received in 2026Non-dilutive funding
25 Aug 2026First patient dosed in DReAMzzExecution
30 Aug 2026USD 20 M buyback program expiry dateCapital-allocation decision point
9 Sep 2026Patient-dosing progress update for DReAMzzExecution
Aug–Sep 2026(Competitor) Definium's DT120 (LSD) positive Phase 3 Voyage (Aug) and Panorama (14 Sep) results in GADRaises the efficacy bar for PSX-001
25 Sep 2026FY2026 10-K/results: net loss USD 19.3 M; cash USD 67.7 M; IHL-675A trial terminated; 12,544,627 shares outstandingAnnual disclosure

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue held from USD 0 Mn in FY2023 to USD 0 Mn in FY2026.
Incannex Healthcare Limited — Income Statement: Revenue & Gross Profit
Series (USD Mn)FY2023FY2024FY2025FY2026
Revenue000.10

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. 1Form 10-K, Incannex Healthcare Inc. — FY2026 (YE 30 Jun 2026) (sec.gov)
  2. 2Form 10-K, Incannex Healthcare Inc. — FY2025 (sec.gov)
  3. 3Form 10-K, Incannex Healthcare Inc. — FY2024 (sec.gov)
  4. 4Form 10-Q — Q3 FY2026 (31 Mar 2026) (sec.gov)
  5. 5Definitive Proxy (DEF 14A) — FY2025, filed 27 Oct 2025 (sec.gov)
  6. 6Form 20-F, Incannex Healthcare Limited — FY2022, FY2023 — SEC EDGAR
  7. 78-K: Redomiciliation — 28 Nov 2023 — SEC EDGAR
  8. 88-K / PR: Reverse stock split — 24–25 Feb 2026 — SEC EDGAR; ir.incannex.com
  9. 98-K / PR: Nasdaq compliance regained — 16–17 Mar 2026 — ir.incannex.com
  10. 10PR: 2025 year in review and 2026 outlook — 14 Jan 2026 — ir.incannex.com
  11. 11PR: FDA Fast Track IHL-42X — 3 Dec 2025 — ir.incannex.com
  12. 12PRs: DReAMzz commencement / screening / first patient — May – Sep 2026 — ir.incannex.com
  13. 13PR: Mind Medicine Australia JV — 17 Jun 2025 — ir.incannex.com
  14. 14PR: Series A warrant cancellation — 28 May 2025 — ir.incannex.com
  15. 15Quartr FY2026 (Q4) earnings summary — FY2026 — quartr.com
  16. 16Stock Titan filing summaries / market-reaction logs — 2025–2026 — stocktitan.net
  17. 17Yahoo Finance quote — 2 Oct 2026 — finance.yahoo.com
  18. 18Apnimed AD109 NDA acceptance — 14 Jul 2026 — drugs.com; prnewswire
  19. 19Definium DT120 Phase 3 GAD results — Aug – Sep 2026 — businesswire.com; pharmatimes.com
  20. 20Aggregator balance-sheet / XBRL histories — FY2023–FY2026 — vcpscanner.com; digrin.com; app.edgar.tools; MarketScreener

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.